Graves甲亢治疗的长期结局:一项8年随访研究
该研究对2003-2005年新诊断的2430例Graves甲亢患者进行8±0.9年随访,实际随访1186例。结果显示,首选抗甲状腺药物(ATD)治疗者最终仅40.3%无需甲状腺激素替代即维持正常甲状腺功能,25.3%患者自感未完全康复。
要点
- 首选ATD者仅50.3%最终避免根治性治疗,40.3%无需左甲状腺素即甲功正常。
- 131I和手术根治后分别有77.3%和96.2%需左甲状腺素替代。
- 随访6-10年时25.3%患者自感未完全康复。
核心结论
- 首选ATD治疗Graves甲亢者仅约半数最终避免根治性治疗,仅约40%无需甲状腺药物即甲功正常。
- 约1/4患者随访6-10年仍自感未完全康复。
研究设计与样本
- 实用型 trial,纳入2003-2005年新诊断Graves甲亢患者2430例,随访8±0.9年,实际随访1186例(60%)。
- 通过问卷和病历回顾收集治疗方式、缓解率、复发、生活质量、人口学、合并症和生活方式数据。
主要发现
- 首选ATD一线治疗缓解率45.3%(351/774),131I治疗81.5%(324/264),手术96.3%(52/54)。
- 第二疗程ATD缓解率29.4%,低于首疗程的45.3%。
- 64.3%(763/1186)患者接受根治性治疗,其中手术23%(278/1186)、131I 43%(505/1186)、两者均用2%(20/1186)。
- 首选ATD(可能加用ATD)者随访时49.7%(385/774)接受了根治性治疗。
- 初始ATD缓解者23%(81/351)、131I治疗者77.3%(204/264)、手术者96.2%(50/52)需左甲状腺素替代。
临床怎么用
- 选择ATD作为Graves甲亢初始治疗时,应告知患者最终避免根治性治疗的几率仅约50.3%,无需甲状腺药物即甲功正常的几率仅约40%。
局限性
- 随访率60%(1186/2430),存在失访偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The treatment efficacy of antithyroid drug (ATD) therapy, radioactive iodine (131I), or surgery for Graves' hyperthyroidism is well described. However, there are a few reports on the long-term total outcome of each treatment modality regarding how many require levothyroxine supplementation, the need of thyroid ablation, or the individual patient's estimation of their recovery. Methods: We conducted a pragmatic trial to determine the effectiveness and adverse outcome in a patient cohort newly diagnosed with Graves' hyperthyroidism between 2003 and 2005 (n = 2430). The patients were invited to participate in a longitudinal study spanning 8 ± 0.9 years (mean ± standard deviation) after diagnosis. We were able to follow 1186 (60%) patients who had been treated with ATD, 131I, or surgery. We determined the mode of treatment, remission rate, recurrence, quality of life, demographic data, comorbidities, and lifestyle factors through questionnaires and a review of the individual's medical history records. Results: At follow-up, the remission rate after first-line treatment choice with ATD was 45.3% (351/774), with 131I therapy 81.5% (324/264), and with surgery 96.3% (52/54). Among those patients who had a second course of ATD, 29.4% achieved remission (vs. the 45.3% after the first course of ATD). The total number of patients who had undergone ablative treatment was 64.3% (763/1186), of whom 23% (278/1186) had received surgery, 43% (505/1186) had received 131I therapy, including 2% (20/1186) who had received both surgery and 131I. Patients who received ATD as first-line treatment and possibly additional ATD had 49.7% risk (385/774) of having undergone ablative treatment at follow-up. Levothyroxine replacement was needed in 23% (81/351) of the initially ATD treated in remission, in 77.3% (204/264) of the 131I treated, and in 96.2% (50/52) of the surgically treated patients. Taken together after 6-10 years, and all treatment considered, normal thyroid hormone status without thyroxine supplementation was only achieved in 35.7% (423/1186) of all patients and in only 40.3% of those initially treated with ATD. The proportion of patients that did not feel fully recovered at follow-up was 25.3%. Conclusion: A patient selecting ATD therapy as the initial approach in the treatment of Graves' hyperthyroidism should be informed that they have only a 50.3% chance of ultimately avoiding ablative treatment and only a 40% chance of eventually being euthyroid without thyroid medication. Surprisingly, 1 in 4 patients did not feel fully recovered after 6-10 years. The treatment for Graves' hyperthyroidism, thus, has unexpected long-term consequences for many patients.
引用
- Sjölin G, Holmberg M, Törring O, et al. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. Thyroid. 2019. PMID: 31482765. doi:10.1089/thy.2019.0085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。